The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
Are you a PhD developmental biologist, biochemist, molecular biologist, biomedical engineer or stem cell biologist interested in changing paradigms and outcomes for cancers of children,
cc-TDI welcomed Claire Newman to cc-TDI as a Social Venture Partners Encore Fellow in August 2023. Claire’s role in Operations Scaling and Optimization includes diving
The Silicon Forest in Hillsboro, OR, January 9, 2024 – The Children’s Cancer Therapy Development Institute was awarded $100,000 in continued support of two research
As we make our final approach to the new year, we want to share a story that embodies the #givingbackchildhood spirit of cc-TDI’s mission. Meet
In August 2023, the cc-TDI team was introduced to the Bliss family, a vibrant and loving family who wanted to make a difference in the
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
In fond remembrance of Ally Anderson, we joyfully celebrate a life that, despite the challenges of pediatric cancer, radiated hope, love, and an unwavering spirit.
Like most of the world, Jessie Munoz didn’t know much about childhood cancer. She had seen the St. Jude commercials of the smiling bald babies,
The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
Are you a PhD developmental biologist, biochemist, molecular biologist, biomedical engineer or stem cell biologist interested in changing paradigms and outcomes for cancers of children,
cc-TDI welcomed Claire Newman to cc-TDI as a Social Venture Partners Encore Fellow in August 2023. Claire’s role in Operations Scaling and Optimization includes diving
The Silicon Forest in Hillsboro, OR, January 9, 2024 – The Children’s Cancer Therapy Development Institute was awarded $100,000 in continued support of two research
As we make our final approach to the new year, we want to share a story that embodies the #givingbackchildhood spirit of cc-TDI’s mission. Meet
In August 2023, the cc-TDI team was introduced to the Bliss family, a vibrant and loving family who wanted to make a difference in the
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
In fond remembrance of Ally Anderson, we joyfully celebrate a life that, despite the challenges of pediatric cancer, radiated hope, love, and an unwavering spirit.
Like most of the world, Jessie Munoz didn’t know much about childhood cancer. She had seen the St. Jude commercials of the smiling bald babies,
EIN: 46-5759569
cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)
Copyright 2024 – Children’s Cancer Therapy Development Institute